Get the Stockscreener App
2.08
0.48%
-0.010
After Hours:
2.07
-0.01
-0.48%
Dare Bioscience Inc stock is traded at $2.08, with a volume of 53,133.
It is down -0.48% in the last 24 hours and up +10.64% over the past month.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
See More
Previous Close:
$2.09
Open:
$2.06
24h Volume:
53,133
Relative Volume:
0.09
Market Cap:
$31.16M
Revenue:
$1.16M
Net Income/Loss:
$-12.02M
P/E Ratio:
-2.0037
EPS:
-1.0381
Net Cash Flow:
$-10.16M
1W Performance:
-0.95%
1M Performance:
+10.64%
6M Performance:
+6.12%
1Y Performance:
-13.33%
1-Day Range:
$2.06
$2.12
1-Week Range:
$2.04
$2.21
52-Week Range:
$1.27
$9.19
Dare Bioscience Inc Stock (DARE) Company Profile
Name
Dare Bioscience Inc
Sector
Industry
Phone
858-926-7655
Address
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
2.08 | 31.61M | 1.16M | -12.02M | -10.16M | -1.0381 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dare Bioscience Inc Stock (DARE) Latest News
Daré Bioscience’s vaginal probiotic is now for sale online - Stock Titan
Dare Bioscience Company Profile & Introduction - Moomoo
Daré Bioscience, Inc.(NasdaqCM: DARE) added to Russell 3000E Growth Benchmark - marketscreener.com
Daré Bioscience, Inc.(NasdaqCM: DARE) added to Russell 3000E Index - marketscreener.com
Daré Bioscience, Inc.(NasdaqCM: DARE) added to Russell Microcap Index - marketscreener.com
Dare Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5 in Virtual Investor What This Means Segment - marketscreener.com
Dare Bioscience Inc (DARE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dare Bioscience, Inc. Actuals & Estimates (NASDAQ:DARE) - TradingView
DARE Forecast — Price Target — Prediction for 2027 - TradingView
Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor 'What This Means” Segment - The Manila Times
Daré Bioscience Highlights Revenue Opportunity as CEO - GlobeNewswire
Dare Bioscience Inc (DARE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Daré Bioscience, Inc. (DARE) Presents at BIO International Convention 2026Slideshow (NASDAQ:DARE) 2026-06-23 - Seeking Alpha
Daré Bioscience Issues New Corporate Investor Presentation - TipRanks
Form 8K Dare Bioscience Inc For: 22 June By Investing.com - Investing.com South Africa
Dare Bioscience (DARE) unveils June 22, 2026 corporate investor presentation - Stock Titan
Dare Bioscience Inc (DARE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Daré Bioscience to Present Corporate Strategy and Participate in Multiple Speaking Engagements at BIO International Convention 2026 - Quiver Quantitative
Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026 - GlobeNewswire
Dare Bioscience Inc (DARE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dare Bioscience Inc (DARE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dare Bioscience Inc (DARE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dare Bioscience Inc (DARE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dare Bioscience Inc (DARE) Institutional Confidence - TradingKey
Dare Bioscience Inc (DARE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ovaprene phase 3 interim data supports potential of monthly hormone-free contraceptive - Contemporary OB/GYN
Dare Bioscience (DARE) Holds Near Support After Marginal DeclineSector ETF Flow - newsline.com
Daré Bioscience Shareholders Back Governance and Capital Plans - The Globe and Mail
Daré Bioscience (NASDAQ: DARE) OKs equity line and boosts incentive plan shares - Stock Titan
Dare Bioscience (DARE) director receives 10,000 stock option grant - Stock Titan
Director Susan L. Kelley receives 10,000 Dare Bioscience (DARE) stock options - Stock Titan
Director at Dare Bioscience (NASDAQ: DARE) receives 10,000 stock options grant - Stock Titan
Director Gregory Matz receives 10,000 Dare Bioscience (DARE) stock options - Stock Titan
Dare Bioscience (DARE) director receives 10,000 stock options at $2.03 strike - Stock Titan
Dare Bioscience Inc Annual Shareholders Meeting Transcript - GuruFocus
Daré Bioscience to launch vaginal probiotic product - Investing.com
Daré Bioscience to launch vaginal probiotic product By Investing.com - Investing.com South Africa
Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules - The Manila Times
New vaginal probiotic aims to support comfort — with 30% launch discount - Stock Titan
Why Investors Are Suddenly Paying Attention to One of Healthcare’s Most Overlooked Markets - Barchart.com
DARE Stock Price, Quote & Chart | DARE BIOSCIENCE INC (NASDAQ:DARE) - ChartMill
Dare Bioscience (DARE) Dips 2.15%, Hovers Above Key Support at $2.17ETF NAV Deviation - newsline.com
Dare Bioscience (DARE) Edges Higher Amid Steady Support LevelsThematic ETF Flow - The Legal Advocate
Daré Bioscience reports interim phase 3 data for Ovaprene By Investing.com - Investing.com Nigeria
Dare Bioscience (DARE) Secures Final $1M Grant from NIH for HPV Treatment - GuruFocus
Daré Bioscience receives second $1M NIH funding tranche - Investing.com UK
Daré Bioscience receives second $1M NIH funding tranche By Investing.com - Investing.com South Africa
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - The Manila Times
Press Release: Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, Its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - Moomoo
NIH backs $2M HPV treatment push targeting cervical cancer cause - Stock Titan
Dare Bioscience Inc (DARE) Stock Price, Quote, News & History - Benzinga
Dare Bioscience Inc Stock (DARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):